BioElectronics receives product approvals
This article was originally published in The Tan Sheet
Health Canada approves BioElectronics Corp.'s Allay Menstrual Pain Therapy product for OTC sale to treat menstrual pain symptoms. The Frederick, Md.-based company also announces June 29 that South Korea's regulators approved its ActiPatch for reducing muscle pain. "With its proven technology and established clinical platform, Allay and ActiPatch are very unique brands in both Canada and Korea," the company said. BioElectronics noted the approvals open doors into new markets. The firm's pain relief products already are available in 44 countries worldwide
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.